This review explores m1A, m5C, and m7G modifications' impact on urological tumors, highlighting potential therapeutic targets.
Malignant tumors of the urinary system, such as kidney cancer, bladder cancer, and prostate cancer, remain a significant challenge despite the various treatment options available. Identifying therapeutic targets for urological tumors is crucial due to the potential for recurrence and metastasis. Recent research has highlighted the importance of RNA modifications in post-transcriptional regulation, impacting various biological functions in urological tumors, including tumorigenesis, progression, metastasis, and drug resistance. However, the specific mechanisms underlying these interactions are not fully understood. This review will focus on exploring the regulatory role of RNA modifications like m1A, m5C, and m7G in urological tumors, shedding light on the pathways and molecular mechanisms involved. This analysis aims to provide new insights for the treatment of urological tumors.
No takes yet. Share an insight, caveat, or question.
Xue et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: